Jii Bum Lee (Jii B Lee)

Publication Activity (10 Years)

Years Active: 2021-2024
Publications (10 Years): 21

Top Topics

Squamous Cell Carcinoma

Metastatic Colorectal Cancer

Epidermal Growth Factor Receptor

Small Cell Lung Cancer

Top Venues

Lung Cancer (Auckland, N.Z.)

Cancer research communications

Clinical cancer research : an official journal of the American Association for Cancer Research

Therapeutic advances in medical oncology

This page only lists publications with an associated author ORCID identifier.

Publications

Jii Bum Lee, Sai-Hong Ignatius Ou
ATTLAS, IMpower151 and ORIENT-31: Dusting off IMpower150 for Post-Osimertinib in EGFR -Mutated NSCLC? Lung Cancer (Auckland, N.Z.) 15 (2024)
Sai-Hong Ignatius Ou, Xiuning Le, Misako Nagasaka, Thanyanan Reungwetwattana, Myung-Ju Ahn, Darren W T Lim, Edgardo S Santos, Elaine Shum, Sally C M Lau, Jii Bum Lee, Antonio Calles, Fengying Wu, Gilberto Lopes, Virote Sriuranpong, Junko Tanizaki, Hidehito Horinouchi, Marina C Garassino, Sanjay Popat, Benjamin Besse, Rafael Rosell, Ross A Soo
Top 20 EGFR+ NSCLC Clinical and Translational Science Papers That Shaped the 20 Years Since the Discovery of Activating EGFR Mutations in NSCLC. An Editor-in-Chief Expert Panel Consensus Survey. Lung Cancer (Auckland, N.Z.) 15 (2024)
Jessica J Lin, Joshua C Horan, Anupong Tangpeerachaikul, Aurélie Swalduz, Augusto Valdivia, Melissa Lynne Johnson, Benjamin Besse, D Ross Camidge, Toshio Fujino, Satoshi Yoda, Linh Nguyen-Phuong, Hayato Mizuta, Ludovic Bigot, Catline Nobre, Jii Bum Lee, Mi Ra Yu, Scot Mente, Yuting Sun, Nancy E Kohl, James R Porter, Matthew D Shair, Viola W Zhu, Enriqueta Felip Font, Byoung Chul Cho, Luc Friboulet, Aaron N Hata, Henry E Pelish, Alexander E Drilon
NVL-655 Is a Selective and Brain-Penetrant Inhibitor of Diverse ALK-Mutant Oncoproteins, Including Lorlatinib-Resistant Compound Mutations. Cancer discovery (2024)
Eun Ji Lee, Seung Yeon Oh, You Won Lee, Ju Young Kim, Min-Je Kim, Tae Ho Kim, Jii Bum Lee, Min Hee Hong, Sun Min Lim, Anke Baum, Lydia Woelflingseder, Harald Engelhardt, Mark Petronczki, Flavio Solca, Mi Ran Yun, Byoung Chul Cho
Discovery of a novel potent EGFR inhibitor against EGFR activating mutations and on-target resistance in NSCLC. Clinical cancer research : an official journal of the American Association for Cancer Research (2024)
Sun Min Lim, Seong-San Kang, Dong Kwon Kim, Soo-Hwan Lee, Chun-Bong Synn, Sujeong Baek, Seung Min Yang, Yu Jin Han, Mi Hyun Kim, Heekyung Han, Kwangmin Na, Youngtaek Kim, Mi Ran Yun, Seok-Young Kim, Youngseon Byeon, Young Seob Kim, Jii Bum Lee, Min Hee Hong, Joshua C Curtin, Bharvin Patel, Isabelle Bergiers, Kyoung-Ho Pyo, Byoung Chul Cho
Exploration of immune-modulatory effects of amivantamab in combination with pembrolizumab in lung and head and neck squamous cell carcinoma. Cancer research communications (2024)
Su-Jin Choi, Jii Bum Lee, Jae Hwan Kim, Min Hee Hong, Byoung Chul Cho, Sun Min Lim
Analysis of tumor mutational burden and mutational landscape comparing whole-exome sequencing and comprehensive genomic profiling in patients with resectable early-stage non-small-cell lung cancer. Therapeutic advances in medical oncology 16 (2024)
Sun Min Lim, Seong-San Kang, Dong Kwon Kim, Soo-Hwan Lee, Chun-Bong Synn, Sujeong Baek, Seung Min Yang, Yu Jin Han, Mi Hyun Kim, Heekyung Han, Kwangmin Na, Youngtaek Kim, Mi Ran Yun, Seok-Young Kim, Youngseon Byeon, Young S Kim, Jii Bum Lee, Min Hee Hong, Joshua C Curtin, Bharvin Patel, Isabelle Bergiers, Kyoung-Ho Pyo, Byoung Chul Cho
Exploration of Immune-Modulatory Effects of Amivantamab in Combination with Pembrolizumab in Lung and Head and Neck Squamous Cell Carcinoma. Cancer research communications 4 (7) (2024)
Sai-Hong Ignatius Ou, Xiuning Le, Misako Nagasaka, Thanyanan Reungwetwattana, Myung-Ju Ahn, Darren W T Lim, Edgardo S Santos, Elaine Shum, Sally C M Lau, Jii Bum Lee, Antonio Calles, Fengying Wu, Gilberto Lopes, Virote Sriuranpong, Junko Tanizaki, Hidehito Horinouchi, Marina C Garassino, Sanjay Popat, Benjamin Besse, Rafael Rosell, Ross A Soo
Top 20 EGFR+ NSCLC Clinical and Translational Science Papers That Shaped the 20 Years Since the Discovery of Activating EGFR Mutations in NSCLC. An Editor-in-Chief Expert Panel Consensus Survey. Lung Cancer (Auckland, N.Z.) 15 (2024)
Eun Ji Lee, Seung Yeon Oh, You Won Lee, Ju Young Kim, Min-Je Kim, Tae Ho Kim, Jii Bum Lee, Min Hee Hong, Sun Min Lim, Anke Baum, Lydia Woelflingseder, Harald Engelhardt, Mark Petronczki, Flavio Solca, Mi Ran Yun, Byoung Chul Cho
Discovery of a Novel Potent EGFR Inhibitor Against EGFR Activating Mutations and On-Target Resistance in NSCLC. Clinical cancer research : an official journal of the American Association for Cancer Research 30 (8) (2024)
Jii Bum Lee, Sai-Hong Ignatius Ou
ATTLAS, IMpower151 and ORIENT-31: Dusting off IMpower150 for Post-Osimertinib in EGFR -Mutated NSCLC? Lung Cancer (Auckland, N.Z.) 15 (2024)
Sun Min Lim, Seong-San Kang, Dong Kwon Kim, Soo-Hwan Lee, Chun-Bong Synn, Sujeong Baek, Seung Min Yang, Yu Jin Han, Mi Hyun Kim, Heekyung Han, Kwangmin Na, Youngtaek Kim, Mi Ran Yun, Seok-Young Kim, Youngseon Byeon, Young S Kim, Jii Bum Lee, Min Hee Hong, Joshua C Curtin, Bharvin Patel, Isabelle Bergiers, Kyoung-Ho Pyo, Byoung Chul Cho
Exploration of Immune-Modulatory Effects of Amivantamab in Combination with Pembrolizumab in Lung and Head and Neck Squamous Cell Carcinoma. Cancer research communications 4 (7) (2024)
Su-Jin Choi, Jii Bum Lee, Jae Hwan Kim, Min Hee Hong, Byoung Chul Cho, Sun Min Lim
Analysis of tumor mutational burden and mutational landscape comparing whole-exome sequencing and comprehensive genomic profiling in patients with resectable early-stage non-small-cell lung cancer. Therapeutic advances in medical oncology 16 (2024)
Sun Min Lim, Seong-San Kang, Dong Kwon Kim, Soo-Hwan Lee, Chun-Bong Synn, Sujeong Baek, Seung Min Yang, Yu Jin Han, Mi Hyun Kim, Heekyung Han, Kwangmin Na, Youngtaek Kim, Mi Ran Yun, Seok-Young Kim, Youngseon Byeon, Young S Kim, Jii Bum Lee, Min Hee Hong, Joshua C Curtin, Bharvin Patel, Isabelle Bergiers, Kyoung-Ho Pyo, Byoung Chul Cho
Exploration of Immune-Modulatory Effects of Amivantamab in Combination with Pembrolizumab in Lung and Head and Neck Squamous Cell Carcinoma. Cancer research communications 4 (7) (2024)
Eun Ji Lee, Seung Yeon Oh, You Won Lee, Ju Young Kim, Min-Je Kim, Tae Ho Kim, Jii Bum Lee, Min Hee Hong, Sun Min Lim, Anke Baum, Lydia Woelflingseder, Harald Engelhardt, Mark Petronczki, Flavio Solca, Mi Ran Yun, Byoung Chul Cho
Discovery of a Novel Potent EGFR Inhibitor Against EGFR Activating Mutations and On-Target Resistance in NSCLC. Clinical cancer research : an official journal of the American Association for Cancer Research 30 (8) (2024)
Sun Min Lim, Jii Bum Lee, Yuko Oya, Jorn Nutzinger, Ross Andrew Soo
Path less Traveled: Targeting Rare Driver Oncogenes in Non-Small-Cell Lung Cancer. JCO oncology practice (2023)
Youngtaek Kim, Joon Yeon Hwang, Dong Kwon Kim, Kwangmin Na, Seul Lee, Sujeong Baek, Seong-San Kang, Seung Min Yang, Mi Hyun Kim, Heekyung Han, Chai Young Lee, Yu Jin Han, Min Hee Hong, Jii Bum Lee, Sun Min Lim, Byoung Chul Cho, Youngjoon Park, Kyoung-Ho Pyo
Polo-like Kinase 4: A Multifaceted Marker Linking Tumor Aggressiveness and Unfavorable Prognosis, and Insights into Therapeutic Strategies. Cancers 15 (18) (2023)
Sun Min Lim, Chang Gon Kim, Jii Bum Lee, Byoung Chul Cho
Patritumab Deruxtecan: Paving the Way for EGFR-TKI-Resistant NSCLC. Cancer discovery 12 (1) (2022)
Jii Bum Lee, Hye Ryun Kim, Sang-Jun Ha
Immune Checkpoint Inhibitors in 10 Years: Contribution of Basic Research and Clinical Application in Cancer Immunotherapy. Immune network 22 (1) (2022)
Yong Jun Lee, Jii Bum Lee, Sang-Jun Ha, Hye Ryun Kim
Clinical Perspectives to Overcome Acquired Resistance to Anti-Programmed Death-1 and Anti-Programmed Death Ligand-1 Therapy in Non-Small Cell Lung Cancer. Molecules and cells 44 (5) (2021)
Jii Bum Lee, Kyoung-Ho Pyo, Hye Ryun Kim
Role and Function of O-GlcNAcylation in Cancer. Cancers 13 (21) (2021)
Jii Bum Lee, Beung-Chul Ahn, Seung Hyun Kim, Young Han Lee, Jung Woo Han, Min Kyung Jeon, Soo Hee Kim, Hyo Song Kim
Prognostic implications of PD-L1 expression in patients with angiosarcoma. Future science OA 7 (5) (2021)